

# Angelo Di Leo

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4151103/angelo-di-leo-publications-by-citations.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172 papers	11,591 citations	53 h-index	106 g-index
186 ext. papers	13,716 ext. citations	6.3 avg, IF	5.72 L-index

#	Paper	IF	Citations
172	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1533-46	10.3	1122
171	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 860-7	2.2	1023
170	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3638-3646	2.2	699
169	Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4594-600	2.2	467
168	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 27-39 <sup>1-7</sup>	2.2	413
167	Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5544-52	2.2	363
166	Dissecting the heterogeneity of triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1879-87	2.2	304
165	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 122-137	59.2	270
164	Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 87-100	21.7	228
163	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. <i>Cancer</i> , <b>2012</b> , 118, 2603-14	6.4	220
162	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 371-382	21.7	200
161	Metabolomics: available results, current research projects in breast cancer, and future applications. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2840-6	2.2	199
160	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1385-1393	21.7	195
159	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3307-29	2.2	185
158	HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 1107-16	12.9	185
157	Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 118, 523-30	4.4	183
156	Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt337	9.7	181

155	MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. <i>Npj Breast Cancer</i> , <b>2019</b> , 5, 5	7.8	176
154	Management of triple negative breast cancer. <i>Breast</i> , <b>2010</b> , 19, 312-21	3.6	148
153	Multifactorial approach to predicting resistance to anthracyclines. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1578-86	2.2	143
152	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , <b>2011</b> , 12, 1134-42	21.7	141
151	Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3103-10	2.2	140
150	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , <b>2019</b> , 393, 1440-1452	40	137
149	HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 7861-70	12.9	137
148	Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3968-75	2.2	131
147	Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. <i>Molecular Oncology</i> , <b>2015</b> , 9, 749-57	7.9	129
146	Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 121-33	9.7	123
145	The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 119, 145-53	4.4	117
144	Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 26107-19	3.3	116
143	Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1574-83	2.2	112
142	The nutritional risk in oncology: a study of 1,453 cancer outpatients. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 1919-28	3.9	108
141	Defining breast cancer intrinsic subtypes by quantitative receptor expression. <i>Oncologist</i> , <b>2015</b> , 20, 474-82	9.7	102
140	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 134, 333-43	4.4	94
139	Targeting triple negative breast cancer: is p53 the answer?. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 541-50	14.4	89
138	Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 22-36	19.4	87

137	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 541-52	19.4	80
136	Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 134, 283-9	4.4	80
135	A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 68012-68022	3.3	79
134	Breast cancer assessment tools and optimizing adjuvant therapy. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 725-32	19.4	75
133	Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. <i>Molecular Oncology</i> , <b>2015</b> , 9, 128-39	7.9	72
132	Uncovering the metabolomic fingerprint of breast cancer. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2011</b> , 43, 1010-20	5.6	71
131	Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 666	5.3	69
130	Metabolomics in cancer: a bench-to-bedside intersection. <i>Critical Reviews in Oncology/Hematology</i> , <b>2012</b> , 84, 1-7	7	67
129	Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 2572-9	6.1	67
128	Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. <i>Molecular Oncology</i> , <b>2012</b> , 6, 437-44	7.9	66
127	Metabolomics in breast cancer: A decade in review. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 67, 88-96	14.4	65
126	DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. <i>Oncologist</i> , <b>2013</b> , 18, 1063-73	5.7	64
125	Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2018</b> , 19, 127-138	21.7	62
124	Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2045-7	2.2	59
123	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 768-776	9.7	55
122	Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. <i>Breast Cancer Research</i> , <b>2009</b> , 11, 205	8.3	55
121	Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1422-1431	12.9	54
120	HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact. <i>Cancer Treatment Reviews</i> , <b>2013</b> , 39, 947-57	14.4	54

119	Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4511-6	12.9	51
118	TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. <i>Molecular Oncology</i> , <b>2014</b> , 8, 508-19	7.9	49
117	Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1680-7	2.2	47
116	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R70	8.3	47
115	Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5552-8 <sup>2</sup>	3.2	43
114	Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). <i>Clinical Breast Cancer</i> , <b>2008</b> , 8, 453-6	3	43
113	Current status of HER2 testing. <i>Oncology</i> , <b>2002</b> , 63 Suppl 1, 25-32	3.6	42
112	International study on inter-reader variability for circulating tumor cells in breast cancer. <i>Breast Cancer Research</i> , <b>2014</b> , 16, R43	8.3	41
111	Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. <i>Psycho-Oncology</i> , <b>2014</b> , 23, 173-82	3.9	41
110	Continued value of adjuvant anthracyclines as treatment for early breast cancer. <i>Lancet Oncology</i> , <b>2015</b> , 16, e362-9	21.7	40
109	Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , <b>2018</b> , 4, 38	7.8	40
108	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 105-114	2.2	38
107	Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. <i>Breast Care</i> , <b>2017</b> , 12, 304-308	2.4	38
106	Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). <i>European Journal of Cancer</i> , <b>2007</b> , 43, 725-35	7.5	38
105	New approaches for improving outcomes in breast cancer in Europe. <i>Breast</i> , <b>2015</b> , 24, 321-30	3.6	37
104	Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 101, 316-324	4	37
103	Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA671-LBA671	2.2	34
102	Using specific cytotoxics with a targeted mind. <i>Breast</i> , <b>2007</b> , 16 Suppl 2, S120-6	3.6	31

101	Topoisomerase II alpha as a marker predicting anthracyclines activity in early breast cancer patients: ready for the primetime?. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 2791-8	7.5	30
100	Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy. <i>Npj Breast Cancer</i> , <b>2018</b> , 4, 41	7.8	30
99	Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1281-8	12.9	29
98	Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. <i>Current Opinion in Oncology</i> , <b>2014</b> , 26, 568-75	4.2	28
97	The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study. <i>PLoS ONE</i> , <b>2013</b> , 8, e62543	3.7	28
96	Recurrence dynamics of breast cancer according to baseline body mass index. <i>European Journal of Cancer</i> , <b>2017</b> , 87, 10-20	7.5	27
95	The Emerging Role of Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy. <i>Cancers</i> , <b>2019</b> , 11,	6.6	27
94	Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1481-9	7.5	26
93	Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?. <i>Cancers</i> , <b>2014</b> , 6, 684-707	6.6	25
92	Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. <i>BMC Medicine</i> , <b>2015</b> , 13, 46	11.4	23
91	The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. <i>Cancer Treatment Reviews</i> , <b>2009</b> , 35, 662-7	14.4	23
90	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TReND Trial. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2131-2139	12.9	22
89	Metabolomics in Breast Cancer: Current Status and Perspectives. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 882, 217-34	3.6	21
88	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 556-563	3.5	20
87	Feasibility of evaluating quality cancer care using registry data and electronic health records: a population-based study. <i>International Journal for Quality in Health Care</i> , <b>2012</b> , 24, 411-8	1.9	20
86	Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 2270-8	7.5	20
85	Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2017</b> , 72, 922-928	6.4	19
84	Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 720-5	2.2	19



83	Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFFECT). <i>European Journal of Cancer</i> , <b>2019</b> , 114, 55-66	7.5	18
82	A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer. <i>Cancer Treatment Reviews</i> , <b>2015</b> , 41, 94-104	14.4	18
81	Chemotherapy for metastatic breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , <b>2004</b> , 16, 37-41.	4.4	18
80	Taxanes in the elderly: can we gain as much and be less toxic?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 70, 262-71	7	16
79	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREN trial. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 71	8.3	14
78	Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes. <i>Breast</i> , <b>2015</b> , 24 Suppl 2, S136-42	3.6	14
77	Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 936-44	2.2	14
76	Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?. <i>Ecancermedicalscience</i> , <b>2013</b> , 7, 299	2.7	14
75	Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 100, 57-68	7	13
74	Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 767-75	2.5	13
73	Adjuvant systemic treatment for individual patients with triple negative breast cancer. <i>Breast</i> , <b>2011</b> , 20 Suppl 3, S135-41	3.6	12
72	Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients. <i>Radiotherapy and Oncology</i> , <b>2009</b> , 90, 116-21	5.3	12
71	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 74, 29-34	14.4	11
70	Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2019</b> , 19, 392-398	3	11
69	Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 386-395	2.2	11
68	The role of abemaciclib in treatment of advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2018</b> , 10, 1758835918776925	5.4	11
67	Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 503-503	2.2	11
66	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , <b>2011</b> , 97, 690-2	1.7	11

65	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3938-3958	2.2	11
64	TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5755-5764	12.9	11
63	A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 170, 329-341	4.4	10
62	Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. <i>Breast</i> , <b>2014</b> , 23, 473-81	3.6	10
61	Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. <i>EPMA Journal</i> , <b>2015</b> , 6, 17	8.8	10
60	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 138, 149-55	4.4	10
59	Triple negative breast cancer: a heterogeneous subgroup defined by what it is not. <i>European Journal of Cancer</i> , <b>2011</b> , 47 Suppl 3, S370-2	7.5	10
58	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2796-2811	24.4	10
57	ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data. <i>BMC Genomics</i> , <b>2018</b> , 19, 960	4.5	10
56	Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. <i>Breast</i> , <b>2012</b> , 21, 336-42	3.6	9
55	TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. <i>Future Oncology</i> , <b>2013</b> , 9, 1477-87	3.6	9
54	Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. <i>Npj Breast Cancer</i> , <b>2019</b> , 5, 26	7.8	8
53	First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. <i>Breast</i> , <b>2018</b> , 38, 144-149	3.6	8
52	Predicting anthracycline benefit: have we made any progress?. <i>Current Opinion in Oncology</i> , <b>2009</b> , 21, 507-15	4.2	8
51	Gastric Cancer Metastatic to the Pituitary Gland: A Case Report. <i>Tumori</i> , <b>2007</b> , 93, 217-219	1.7	8
50	Mortality associated with irinotecan plus bolus fluorouracil/leucovorin. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1145-6	2.2	8
49	A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1002-1002	2.2	8
48	Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 181, 347-359	4.4	7



47	Re-searching anthracycline therapy. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 123, 171-5	4.4	7
46	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 93, 102136	14.4	7
45	De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer. <i>Breast</i> , <b>2017</b> , 34 Suppl 1, S13-S18	3.6	6
44	Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 1954-5	2.2	6
43	Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. <i>Cancer Treatment Reviews</i> , <b>2002</b> , 28, 275-90	14.4	6
42	Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies. <i>Npj Breast Cancer</i> , <b>2021</b> , 7, 11	7.8	6
41	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 170, 351-360	4.4	5
40	p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. <i>International Journal of Oncology</i> , <b>2018</b> , 52, 424-432	4.4	5
39	A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
38	A meta-analysis of clinical benefit rates for fulvestrant 500mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. <i>Breast Cancer</i> , <b>2019</b> , 26, 703-711	3.4	4
37	Using CTCs for pharmacogenomic analysis. <i>Pharmacological Research</i> , <b>2016</b> , 106, 92-100	10.2	4
36	Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. <i>Anticancer Research</i> , <b>2018</b> , 38, 4839-4845	2.3	4
35	Targeting Metabolomics in Breast Cancer. <i>Current Breast Cancer Reports</i> , <b>2012</b> , 4, 249-256	0.8	4
34	Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 1735-6; author reply 1736-7	9.7	4
33	Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?. <i>Breast</i> , <b>2009</b> , 18 Suppl 3, S18-24	3.6	4
32	Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer. <i>Future Oncology</i> , <b>2011</b> , 7, 173-86	3.6	4
31	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
30	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 959-967	8.7	3

29	A multifactorial Consensus Signature by analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer. <i>Npj Breast Cancer</i> , <b>2015</b> , 1, 15003	7.8	3
28	Adjuvant chemotherapy: which patient? What regimen?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2013</b> , 3-8	7.1	3
27	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 1917-1929	7.5	3
26	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 504-512	12.9	3
25	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2720-2731	2.2	3
24	RE: Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109, 1	9.7	2
23	Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2007</b> , 62, 1-8	7	2
22	Abstract CT099: The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3 <b>2018</b> ,		2
21	Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
20	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919891608	5.4	2
19	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. <i>BMC Cancer</i> , <b>2018</b> , 18, 932	4.8	2
18	The continued evidence from overviews: what is the clinical utility?. <i>Breast</i> , <b>2013</b> , 22 Suppl 2, S8-11	3.6	1
17	Predictive molecular markers of anthracycline effectiveness in early breast cancer. <i>European Journal of Cancer, Supplement</i> , <b>2011</b> , 9, 16-21	1.6	1
16	In silico analysis of a multifactorial consensus signature (ConSig) for predicting response to anthracycline (A)-based neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1025-1025	2.2	1
15	Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1048-1048	2.2	1
14	Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer. <i>Breast</i> , <b>2019</b> , 48 Suppl 1, S81-S84	3.6	1
13	Circulating Tumour Cells as Liquid Biopsy in Breast Cancer: Advancing from Prognostic to Predictive Potential. <i>Current Breast Cancer Reports</i> , <b>2015</b> , 7, 53-58	0.8	
12	Relative benefits of newer adjuvant chemotherapy regimens in luminal breast cancer subtypes. <i>Breast</i> , <b>2016</b> , 27, 189	3.6	

11	Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution. <i>Breast Journal</i> , <b>2019</b> , 25, 1225-1229	1.2
10	Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents. <i>Current Breast Cancer Reports</i> , <b>2011</b> , 3, 24-33	0.8
9	Ode to a past emperor. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2938-40	2.2
8	A RB-1 loss of function gene-signature (RBSig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 570-570	2.2
7	Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy: A Breast International Group (BIG) 1-98 sub-analyses.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 538-538	2.2
6	Survher: A retrospective multicenter study comparing demographic and tumor characteristics of clinical trials versus clinical practice patients with HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 640-640	2.2
5	A prospective study to evaluate the Vulnerable Elders Survey-13 (VES-13) as a tool to identify frail older cancer patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9546-9546	2.2
4	Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 630-630	2.2
3	Meta-analysis of clinical outcomes to second-line endocrine therapy for visceral and non-visceral metastases.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 568-568	2.2
2	Serum metabolomics as biomarkers to differentiate early from metastatic disease and predict relapse in elderly colorectal cancer (CRC) patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10042-10042	2.2
1	In Reply to Belkacemi and Tsoutsou. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 467-468	4